News

Filter

Current filters:

Astellas PharmaVaccines

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

15-01-2014

Japanese drug major Astellas Pharma and partner UMN Pharma have announced promising summary results for…

Asia-PacificASP7374Astellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceuticalResearchUMN PharmaVaccines

Negative FDA news for AVEO's tivozanib and Dynavax' hep B vaccine

11-06-2013

US biotech firm AVEO Oncology (Nasdaq: AVEO) says that it has received a complete response letter from…

Anti-viralsAstellas PharmaAVEO OncologyBiotechnologyDynavax TechnologiesHeplisavNorth AmericaOncologyPharmaceuticalRegulationtivozanibVaccines

Astellas ends FLT3 deal with Ambit; reports on flu vaccine ASP7374

12-03-2013

The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) and USA-based privately held firm…

Ambit BiosciencesASP7374Astellas PharmaLicensingOncologyPharmaceuticalquizartinibResearchVaccines

Astellas to use Abbott's CMV assay for vaccine trial

06-09-2012

US health care major Abbott Laboratories (NYSE: ABT) says that it has signed an agreement to collaborate…

Abbott LaboratoriesAnti-viralsAstellas PharmaPharmaceuticalResearchTransVaxVaccines

PDUFA Action Date for Astellas enzalutamide; Urogenix facility to close

07-08-2012

The US Food and Drug Administration has assigned a Prescription Drug User Fee Act (PDUFA) action date…

Astellas PharmaenzalutamideGenito-urinaryMedivationOncologyPharmaceuticalRegulationResearchUrogenixVaccines

Vical to earn as much as $130 million from TransVax deal with Astellas

18-07-2011

US drug developer Vical (Nasdaq: VICL) saw its share price leap 11.6% to $4.80 after it revealed that…

Astellas PharmaGlobalLicensingPharmaceuticalResearchTransVaxVaccinesVical

COMPANY SPOTLIGHT

Menarini

Back to top